Enliven Therapeutics Inc ELVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Enliven Therapeutics to Present at Upcoming Investor Conferences
-
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
-
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
-
Enliven Shares Climb on Positive Leukemia Drug Trial Data
Trading Information
- Previous Close Price
- $45.84
- Day Range
- $45.70–47.23
- 52-Week Range
- $14.79–62.32
- Bid/Ask
- $45.70 / $47.21
- Shares Outstanding
- 73.27M
- Market Cap
- $3.39B
- Volume/Avg
- 405 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 67
Valuation
|
Metric
|
ELVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.78 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELVN
|
|---|---|
Quick Ratio | 63.21 |
Current Ratio | 64.07 |
Interest Coverage | — |
Quick Ratio
ELVN
Profitability
|
Metric
|
ELVN
|
|---|---|
Return on Assets (Normalized) | −11.44% |
Return on Equity (Normalized) | −11.74% |
Return on Invested Capital (Normalized) | −15.07% |
Return on Assets
ELVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#Lxd%ll | LOCK|&v#g< | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>$rmdtk | LOCK|b^d?? | $76B | |||
| Moderna Inc
MRNA
| LOCK|YBTq^Jy | LOCK|$v | $75B | |||
| argenx SE ADR
ARGX
| LOCK|z!YGxC! | LOCK|%R | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<f$v^Dm | LOCK|s< | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|y@?$F@W | LOCK|>%><c | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|v?jSHZ$@ | LOCK|y!M! | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|%RvwJss | LOCK|rY | $24B | |||
| Incyte Corp
INCY
| LOCK|Sc$JXr | LOCK|TQ> | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<qbz?B | LOCK|jkL | $15B |
United States